For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Cannabis debate leaves many doctors in the weeds
Wednesday 28 August 2019, 08:00 AM

Michelle Glass, head of pharmacology and toxicology at the University of Otago, says cannabidiol’s mechanism of action isn’t known
Journalists Alan Perrott and Cliff Taylor provide more coverage from the recent RNZCGP Conference for General Practice
I’m shocked that I might be expected to prescribe something that hasn’t gone through clinical trials
The lack of clinical studies into medicina
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.